Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) and PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Earnings and Valuation
This table compares Coloplast A/S and PROCEPT BioRobotics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coloplast A/S | $4.13 billion | 3.92 | $538.49 million | $0.19 | 37.84 |
| PROCEPT BioRobotics | $308.05 million | 3.50 | -$95.57 million | ($1.94) | -9.70 |
Coloplast A/S has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Coloplast A/S and PROCEPT BioRobotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coloplast A/S | 9.68% | 39.27% | 11.54% |
| PROCEPT BioRobotics | -32.53% | -30.62% | -22.10% |
Volatility and Risk
Coloplast A/S has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Insider & Institutional Ownership
89.5% of PROCEPT BioRobotics shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Coloplast A/S and PROCEPT BioRobotics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coloplast A/S | 1 | 1 | 0 | 1 | 2.33 |
| PROCEPT BioRobotics | 2 | 9 | 2 | 3 | 2.38 |
PROCEPT BioRobotics has a consensus price target of $25.50, suggesting a potential upside of 35.49%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Coloplast A/S.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
